Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion-Reference-Cited by-同舟云学术

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Published:2012-07 Issue:7408 Volume:487 Page:500-504
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Straussman Ravid,Morikawa Teppei,Shee Kevin,Barzily-Rokni Michal,Qian Zhi Rong,Du Jinyan,Davis Ashli,Mongare Margaret M.,Gould Joshua,Frederick Dennie T.,Cooper Zachary A.,Chapman Paul B.,Solit David B.,Ribas Antoni,Lo Roger S.,Flaherty Keith T.,Ogino Shuji,Wargo Jennifer A.,Golub Todd R.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature11183.pdf

Reference30 articles.

1. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010)

2. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011)

3. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)

4. Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714 (2012)

5. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nature Rev. Cancer 9, 239–252 (2009)

Cited by 1534 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming therapy resistance in pancreatic cancer: New insights and future directions;Biochemical Pharmacology;2024-11

2. Emerging trends in oncology: a comprehensive literature review;Surgery and Oncology;2024-09-12

3. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

4. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24